-
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
29 Mar 2024 12:21 GMT
AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, …
-
The 3 Best Biotech Stocks to Buy in Q2 2024
29 Mar 2024 11:52 GMT
… consider buying.
Bristol-Myers Squibb (BMY)
Source: IgorGolovniov / Shutterstock.com
Bristol-Myers Squibb (NYSE:BMY … be for the revenue or earnings growth. It is a well …
-
Bristol Myers Squibb completes $14 billion acquisition of Karuna Therapeutics from PureTech
19 Mar 2024 13:57 GMT
… , chief executive officer of Bristol Myers Squibb.
"Importantly, … of the acquisition underscores Bristol Myers Squibb's … and non-GAAP earnings per share. Bristol Myers Squibb plans … PureTech, Karuna, and Bristol Myers Squibb exemplifies the industry…
-
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics
18 Mar 2024 20:10 GMT
… Boerner, Ph.D., CEO, Bristol Myers Squibb. “Importantly, this … to Bristol Myers Squibb’s non-GAAP diluted earnings per … and portfolio prioritization. Bristol Myers Squibb’s cash flows … with past practice, Bristol Myers Squibb generally provides updates …
-
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
18 Mar 2024 14:12 GMT
… from Bristol Myers Squibb is as follows:
Bristol Myers Squibb … counsel.
About Bristol Myers Squibb
Bristol Myers Squibb is a … Karuna by Bristol Myers Squibb and Bristol Myers Squibb’s … GAAP earnings and related EPS information because Bristol Myers Squibb …
-
Bristol Myers Squibb Completes Acquisition Of Karuna Therapeutics - Quick Facts
18 Mar 2024 13:36 GMT
Bristol Myers Squibb (BMY) has successfully … a wholly owned subsidiary of Bristol Myers Squibb. The company said, … be dilutive to non-GAAP earnings per share by approximately $ … financing cost of the transaction.
Bristol Myers Squibb noted that the transaction …
-
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
18 Mar 2024 12:54 GMT
… legal counsel.
About Bristol Myers Squibb
Bristol Myers Squibb is a … Karuna by Bristol Myers Squibb and Bristol Myers Squibb’s … GAAP earnings and related EPS information because Bristol Myers Squibb … of Bristol Myers Squibb’s business nor reflect Bristol Myers …
-
Spotlight on Bristol-Myers Squibb: Analyzing the Surge in Options Activity
12 Mar 2024 16:37 GMT
… move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb BMY … $43.1K
342
0
About Bristol-Myers Squibb
Bristol-Myers Squibb discovers, develops, and markets drugs … to be may be overbought.
Earnings announcement expected in 44 days …
-
Exelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024
28 Mar 2024 19:53 GMT
… $208m last year, representing earnings per share of $0.65 … translates to a price to earnings ratio, based on Exelixis… In 2024 Already approved alongside Bristol-Myers Squibb's (BMY) immune … zanzalintinib clinical studies (Q3 earnings update)As we can see …
-
GLP-1 surge, oncology stars to power industry's earnings growth over the next 18 months: Moody's
15 Mar 2024 16:37 GMT
… the industry’s overall earnings performance has been … cancer blockbusters from Merck, Bristol Myers Squibb, Roche, AstraZeneca and … in 2026.
Another potential earnings pressure is more patent … AbbVie’s Humira and Bristol Myers Squibb’s Remlivid.
Stelara …